Table 2.
Infants of HBsAg+, HBeAg+ mothers | Infants of HBsAg+, HBeAg− mothers | Immunogenicity in low-risk infants (infants or children of HBsAg− mothers) | |
---|---|---|---|
HBIG only (Beasley et al. 1983b) | |||
One dose, 1.0 mL | HBsAg+, 54%, efficacy 45% | – | – |
Three doses, 0.5 mL | HBsAg+, 26%, efficacy 75% | ||
Placebo | HBsAg+, 92% | ||
HBV plasma vaccine | Vaccine, three doses (RP Beasley and L-Y Hwang, unpubl.) 1 wk, 1, 6 mo, HBsAg+, 23% 1, 2, 6 mo, HBsAg+, 38% Placebo HBsAg+, 88% |
Vaccine, four doses (Tsai et al. 1984), HBsAg+, 0% Placebo, HBsAg+, 5.3% |
Anti-HBs (Lee et al. 1983) After one dose, 48% After two doses, 96% After three doses, 100% |
Combination of HBV plasma vaccine and HBIG, 0.5 mL/dose | HBIG birth, 3 mo + vaccine, 3, 4, 9 mo, HBsAg 2.0% (Beasley et al. 1983c) | HBIG + vaccine, 0, 1, 6 mo, HBsAg+, <1% (Yang et al. 2003) | – |
HBIG birth + vaccine 0, 1, 6 mo, HBsAg+, 6.0% (Beasley et al. 1983c) | Vaccine, 0, 1, 6 mo, HBsAg+ <1% | ||
HBIG birth + vaccine, 1, 2, 7 mo, HBsAg+, 8.6% (Beasley et al. 1983c) | |||
HBIG birth + vaccine, 0, 1, 2, 12 mo, HBsAg+, 11% (Hsu et al. 1988) | |||
Placebo, HBsAg+, 88.1% (Beasley et al. 1983c) | |||
Combination of HBV recombinant vaccine + one dose HBIG, 0.5 mL | HBIG + vaccine 0, 1, 6 mo, HBsAg+, 3.3% (Lee et al. 1991) HBIG + vaccine, 0, 1, 6 mo, HBsAg+, 9.26% (Chen et al. 2012) |
HBIG + vaccine 0, 1, 6 mo, HBsAg+, 0.14% (Chen et al. 2012) Vaccine, 0, 1, 6 mo, HBsAg+, 0.29% |
– |
aHBsAg+ rate in high-risk infants (in comparison to controls with no vaccine or HBIG).